Moody National Bank Trust Division continued to hold its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,423 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $880,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares in the last quarter. Penserra Capital Management LLC raised its stake in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. Webster Bank N. A. raised its stake in Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the 1st quarter worth $143,000. Institutional investors and hedge funds own 73.97% of the company’s stock.

Several equities research analysts recently commented on the stock. Leerink Swann reiterated a “market perform” rating and set a $87.00 price target (up from $82.00) on shares of Gilead Sciences in a research note on Wednesday. Royal Bank Of Canada assumed coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Eleven equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $84.29.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.27 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The stock has a market cap of $108.74 billion, a P/E ratio of 9.04 and a beta of 1.19. The firm has a 50 day moving average of $77.54 and a 200 day moving average of $70.38.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the firm posted $3.08 EPS. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/24/moody-national-bank-trust-division-has-880000-holdings-in-gilead-sciences-inc-gild.html.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,819 shares of company stock valued at $36,740,240. Insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.